Our strategy is based on conquest through innovation, thanks to the adaptation of our industrial tool, the development of a one-stop shop approach as well as strengthening the skills of our teams.
Conquest by innovation
Health innovation is a real long-term challenge which requires perseverance to achieve all the promises of science.
Driven by our new direction aimed at taking more risks, we are committed to an innovation approach from the first phases and over the long term, to support the implementation of projects and value creation.
As such, Cenexi is positioned as a privileged partner of startups and innovative biotechs to ensure the success of their developments in cutting-edge therapeutic areas, such as oncology and vaccines.
IN 2026/2027, 80% OF CENEXI’S BUSINESS WILL BE STERILE (AGAINST 70% IN 2022).
MODERNIZATION DRIVEN BY THE ADAPTATION OF PRODUCTION FACILITIES, THE DEVELOPMENT OF A NEW APPROACH AND THE ENHANCEMENT OF EMPLOYEE SKILLS
Faced with profound changes in the biopharmaceutical industry, Cenexi has undertaken its own transformation and is changing:
- Investment to adapt the production facilities on all our sites
- Implementation of a one-stop shop approach (from the development phase to industrialization and commercial activity) proposed to our clients, which enables them to accelerate and secure the marketing of their innovative drugs
- Strengthening of teams, particularly in management positions, and creation of support functions to enable everyone to develop their skills and focus on value creation
- Change of culture towards more independence, accountability, and audacity
- International ambition: development of other markets in Europe, the USA, Asia, etc.
THE STARTUP CROSSJECT
Since 2016, we have supported the startup Crossject in the development, filling, and final assembly of Zeneo needle-free injectors, the result of twenty years of R&D and protected by 400 patents, on our Braine-l’Alleud site in Belgium. It is a complex process requiring custom-made production equipment – resulting in a patent – to fill the single-use auto-injector used in emergency situations. In 2021, the production ramp-up stage began with the gradual implementation of the production capacities necessary for commercial operation over the next few years.
THE BIOTECH OSE IMMUNOTHERAPEUTICS
Cenexi is also involved in the fight against COVID-19 since an agreement was signed in 2021 with OSE Immunotherapeutics, a biotech developing innovative immunotherapies, according to which the Group will manufacture the clinical batches which will be used in the development phases of CoVepiT, the next-generation multi-target vaccine against Covid-19.
THE BIOPHARMACEUTICAL COMPANY HUMANIGEN
In February 2022, Cenexi entered into a partnership with Humanigen, an American biopharmaceutical company specializing in the prevention and treatment of an overactive immune response called cytokine shock syndrome. This agreement concerns the transfer of technology and expertise from Humanigen to Cenexi in order to manufacture, on our Hérouville-Saint-Clair site, batches of lenzilumab, one of the most promising treatments against serious forms of Covid-19, for the next five years.